We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Metabolon Technology Now Available in Germany
News

Metabolon Technology Now Available in Germany

Metabolon Technology Now Available in Germany
News

Metabolon Technology Now Available in Germany

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Metabolon Technology Now Available in Germany"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Helmholtz Zentrum Muenchen-Metabolon Joint Metabolomics Laboratory has successfully passed a series of stringent quality control processes and reviews, and has officially begun operations. Validation of this lab follows closely behind Shanghai Jiao Tong University Lab in China, which received the Company’s validation last month. The Helmholtz Zentrum Muenchen validation will further expand Metabolon’s commercial sample processing scope and gives the Company an important entry into the European market. This comes after the publication of “Human Metabolic Individuality in Biomedical and Pharmaceutical Research” in the journal Nature in 2011, which was carried out by researchers at the Helmholtz Zentrum Muenchen, the Wellcome Trust/Sanger Centre, King’s College and Metabolon, Inc.

“This is Metabolon’s second successful joint lab launch and fully demonstrates the organization’s commitment to replicating our mass spectrometry process for the benefit of metabolomics research,” stated Metabolon CEO John Ryals.

Advertisement